CCP-RIZATRIPTAN ODT TABLET (ORALLY DISINTEGRATING)

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

Disponibbli minn:

CELLCHEM PHARMACEUTICALS INC.

Kodiċi ATC:

N02CC04

INN (Isem Internazzjonali):

RIZATRIPTAN

Dożaġġ:

5MG

Għamla farmaċewtika:

TABLET (ORALLY DISINTEGRATING)

Kompożizzjoni:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

6

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

SELECTIVE SEROTONIN AGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0137841001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2023-08-03

Karatteristiċi tal-prodott

_CCP-Riztriptan ODT _
_Page 1 of 34_
PRODUCT MONOGRAPH
PR
CCP-RIZATRIPTAN ODT
Rizatriptan Benzoate Orally Disintegrating Tablets
5 mg and 10 mg Rizatriptan (as Rizatriptan Benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Date of Revision:
June 19, 2017
CellChem Pharmaceuticals Inc.
30 Concourse Gate, Unit 1
Ottawa, Ontario
K2E 7V7
Control #
205269
_CCP-Riztriptan ODT _
_Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
................................................................................3
INDICATIONS AND CLINICAL USE
......................................................................................3
CONTRAINDICATIONS
...........................................................................................................3
WARNINGS AND PRECAUTIONS
..........................................................................................4
ADVERSE REACTIONS
..........................................................................................................10
DRUG INTERACTIONS
..........................................................................................................16
DOSAGE AND ADMINISTRATION
......................................................................................18
OVERDOSAGE
.........................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
....................................................................19
STORAGE AND STABILITY
..................................................................................................22
SPECIAL HANDLING INSTRUCTIONS
...............................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................................23
PART II: SCIENTIFIC INFORMATION
..............................................................................
27
PHARMACEUTICAL INF